The Efficacy of Oral/Intravenous Corticosteroid Use in COVID-19 Patients: A Systematic Review.

Autor:	Latarissa IR; Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia.; Medication Therapy Adherence Clinic (MTAC), Universitas Padjadjaran, Sumedang, Indonesia., Rendrayani F; Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia., Iftinan GN; Medication Therapy Adherence Clinic (MTAC), Universitas Padjadjaran, Sumedang, Indonesia., Suhandi C; Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia., Meiliana A; Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia.; Prodia Clinical Laboratory, Central Jakarta, Indonesia., Sormin IP; Faculty of Pharmacy, University of 17 August 1945 Jakarta, Jakarta, Indonesia.; Prodia Diacro Laboratories, Jakarta, Indonesia., Barliana MI; Department of Biological Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia.; Center of Excellence for Pharmaceutical Care Innovation, Universitas Padjadjaran, Sumedang, Indonesia., Lestari K; Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia.; Medication Therapy Adherence Clinic (MTAC), Universitas Padjadjaran, Sumedang, Indonesia.; Center of Excellence for Pharmaceutical Care Innovation, Universitas Padjadjaran, Sumedang, Indonesia.
Jazyk:	angličtina
Zdroj:	Journal of experimental pharmacology [J Exp Pharmacol] 2024 Oct 01; Vol. 16, pp. 321-337. Date of Electronic Publication: 2024 Oct 01 (Print Publication: 2024).
DOI:	10.2147/JEP.S484596
Abstrakt:	The COVID-19 pandemic is prompting extensive investigation into potential treatments, including the use of corticosteroids to manage inflammation and mitigate severe disease outcomes. Therefore, this systematic review aimed to evaluate the efficacy of oral/intravenous corticosteroids in the management of COVID-19. A comprehensive search was conducted across major scientific databases such as MEDLINE, Scopus, and Cochrane for relevant studies published from 2019-2024. The inclusion criteria included studies investigating the use of oral/intravenous corticosteroids in COVID-19 patients >18 years with a randomized placebo-controlled trial method. Non-placebo-controlled studies, studies using combined treatments with other drugs, as well as protocol articles, conference proceedings, review articles, and non-English studies were excluded. A narrative synthesis approach was adopted given the significant methodological diversity. The results showed that a total of 12 studies met the inclusion criteria covering the use of three drugs, including dexamethasone (three), hydrocortisone (two), and methylprednisolone (seven). The outcome parameters used for each study were different. Among the total 12 studies, five showed insignificant results for hydrocortisone (two) and methylprednisolone (three), while others reported significant results. This systematic review suggested that oral/intravenous corticosteroids might confer clinical benefits in the management of COVID-19, particularly in reducing mortality and severe disease outcomes. However, further investigation was needed to establish standardized protocols regarding dosage, duration, and safety considerations to optimize efficacy and minimize potential adverse effects. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (© 2024 Latarissa et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu